DOCSLIB.ORG

ACCP Toolkit the 2016 ACCP Pharmacotherapy Didactic Curriculum Toolkit

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
ACCP Toolkit the 2016 ACCP Pharmacotherapy Didactic Curriculum Toolkit ACCP Toolkit The 2016 ACCP Pharmacotherapy Didactic Curriculum Toolkit 2016 Educational Afairs Committee, American College of Clinical Pharmacy Terry L. Schwinghammer (Chair), Andrew J. Crannage (Vice Chair), Eric G. Boyce, Bridget Bradley, Alyssa Christensen, Henry M. Dunnenberger, Michelle Fravel, Holly Gurgle, Drayton A. Hammond, Jennifer Kwon, Douglas Slain, and Kurt A. Wargo. Approved by the American College of Clinical Pharmacy Board of Regents on July 18, 2016. The purpose of the 2009 and 2016 ACCP Pharmacother- ORGAN SYSTEMS AND DISEASE STATE TOPICS apy Didactic Curriculum Toolkits is to provide guid- ance to schools and colleges of pharmacy in developing, Cardiovascular Disorders maintaining, and modifying their curricula.1,2 The 2016 1 Acute coronary syndromes (STEMI, NSTEMI, unstable ACCP Educational Affairs Committee reviewed recent angina) medical literature and other documents to identify dis- 1 Atherosclerotic cardiovascular disease, primary ease states that are responsive to drug therapy. Disease prevention frequency, socioeconomic burden to society, and impact 1 Atherosclerotic cardiovascular disease, secondary of pharmacist involvement in medication therapy were prevention considered in determining which topics to include in the updated pharmacotherapy toolkit. This updated toolkit 1 Arrhythmias, atrial (e.g., atrial fbrillation) is intended to provide valuable guidance to schools and 1 Basic life support (BLS) colleges of pharmacy as they develop, maintain, and 1 Dyslipidemia modify their curricula to keep pace with major scientific 1 Heart failure, chronic advances and practice changes. 1 Hypertension In the 2016 toolkit, diseases and content topics are 1 Ischemic heart disease, stable organized by organ system, when feasible, and grouped 1 Venous thromboembolism into tiers defined by practice competency. Within each organ system, topics are listed by tier level and then al- 2 Advanced cardiac life support (ACLS) phabetically within tiers. The tier levels assigned by the 2 Arrhythmias, ventricular 2016 Educational Affairs Committee differ from those 2 Drug-induced cardiac disease of the 2009 toolkit. Tier assignments are intended for use only as a guide within the context of individual col- 2 Heart failure, acute decompensated lege or school priorities. 2 Hypertensive crises 2 Peripheral arterial disease Competency-Based Tier Defnitions: 2 Pulmonary arterial hypertension 2 Stroke (ischemic, hemorrhagic, and transient ischemic 1. Students receive education and training on this attack) topic to prepare them to provide collaborative, pa- tient-centered care on graduation and licensure. 2 Valvular heart diseases 3 Aneurysm 2. Students receive education and training on this topic, but additional knowledge or skills may be re- 3 Aortic dissection quired after graduation (e.g., residency training) to 3 Cardiomyopathies prepare them to provide collaborative, direct patient 3 Pericarditis care. Dermatologic Disorders 3. Students and residents may not receive education 1 Acne vulgaris and training on this topic; rather, they will be ex- 1 Burn injuries, minor (e.g., sunburn, self-treated burns) pected to obtain the required knowledge and skills 1 Dermatitis (e.g., atopic, contact, diaper) on their own to provide collaborative, direct patient care if required in their practice. 2 Dermatologic Disorders (continued) Gastrointestinal Disorders (continued) 1 Drug-induced dermatologic disorders (e.g., drug reaction 2 Peptic ulcer disease (including stress-related mucosal with eosinophilia and systemic symptoms [DRESS], injury, gastrointestinal bleeding) Stevens-Johnson syndrome, toxic epidermal necrolysis) 2 Pancreatitis (acute, chronic, and drug-induced) 1 Wounds, minor (e.g., lacerations, punctures, bites, 3 Celiac disease incisions, abrasions, avulsions) 3 Liver diseases, metabolic (e.g., hemochromatosis, Wilson 2 Alopecia disease) 2 Photoaging (e.g., actinic keratosis, solar lentigines) Gynecologic and Obstetrical Disorders 2 Psoriasis 1 Contraception 2 Wounds, major (e.g., pressure ulcers) 1 Lactation (e.g., drugs and breastfeeding) 3 Burn injuries, major 1 Menopausal symptoms (e.g., hot fashes, vaginal dryness, Ear, Nose, and Troat Disorders vulvovaginal atrophy) 1 Allergic rhinitis 1 Pregnancy (e.g., pregnancy testing, nutrition & 1 Cerumen impaction supplementation, drug dosing, teratogenicity, nausea/ vomiting) 1 Cough 2 Diabetes mellitus, gestational 1 Otitis externa (swimmer’s ear) 2 Endometriosis and uterine fbroids 1 Rhinorrhea 2 Female sexual dysfunction 1 Sore throat 2 Infertility 3 Ménière disease 2 Labor and delivery (e.g., labor induction, preterm labor) Endocrine Disorders 2 Menstrual cycle disorders (e.g., dysmenorrhea, 1 Diabetes, type 1 menorrhagia) 1 Diabetes, type 2 2 Pregnancy-induced hypertension, preeclampsia, 1 Hypothyroidism eclampsia 2 Adrenal gland disorders (e.g., adrenal insufciency, 3 Polycystic ovary syndrome hypercortisolism) 3 Pregnancy termination 2 Drug-induced endocrine disorders Hematologic Disorders 2 Hyperglycemic crises (diabetic ketoacidosis [DKA], 1 Anemias (e.g., iron defciency, vitamin B12 defciency, hyperosmolar hyperglycemic state [HHS]) folic acid defciency, chronic disease/infammation) 2 Hyperthyroidism 1 Drug-induced hematologic disorders 2 Male hypogonadism 2 Aplastic anemia 3 Pituitary gland disorders (e.g., growth hormone 2 Coagulation disorders (e.g., hemophilia, von Willebrand defciency, acromegaly, hyperprolactinemia) disease, antiphospholipid syndrome, clotting factor 3 Transgender health defciencies) Gastrointestinal Disorders 2 Sickle cell disease 1 Constipation 3 Disseminated intravascular coagulation 1 Diarrhea (including traveler’s diarrhea) 3 Platelet disorders (e.g., idiopathic thrombocytopenic 1 Drug-induced hepatic disorders purpura, thrombotic thrombocytopenic purpura) 1 Gastroesophageal refux disease 3 Porphyrias 1 Nausea & vomiting, simple (e.g., acute viral Immunologic Disorders gastroenteritis, overindulgence, motion sickness) 1 Allergies/drug hypersensitivities (e.g., anaphylaxis, 2 Cirrhosis, end-stage liver disease, and complications desensitization) (e.g., portal hypertension, ascites, varices, hepatic 2 Solid organ transplantation (e.g., heart, liver, lung, encephalopathy, hepatorenal syndrome) kidney; including immunosuppressive therapy) 2 Infammatory bowel disease (Crohn disease, ulcerative 2 Systemic lupus erythematosus colitis) 3 Immunodefciency 2 Irritable bowel syndrome Infectious Diseases 2 Nausea & vomiting, complex (e.g., postoperative, 1 Antimicrobial regimen selection chemotherapy-induced) 1 Clostridium difcile infection 2 Nonalcoholic steatohepatitis 3 Infectious Diseases (continued) Infectious Diseases (continued) 1 Fungal infections, superfcial (e.g., vulvovaginal and 3 Bacterial infections, miscellaneous (e.g., nocardiosis, esophageal candidiasis, dermatophytoses) actinomycosis, Tropheryma whipplei [Whipple disease]) 1 Immunization (including vaccines, toxoids, and other 3 Mycobacterial infections, other (leprosy, nontuberculous immunobiologics) mycobacterial infections) 1 Infuenza virus infection 3 Viral infections, miscellaneous (West Nile, Ebola, dengue 1 Lower respiratory tract infections fever) 1 Skin and sof tissue infections Musculoskeletal and Connective Tissue Disorders 1 Upper respiratory tract infections (e.g., otitis media, 1 Gout and hyperuricemia sinusitis, pharyngitis, bronchitis) 1 Osteoarthritis 1 Urinary tract infections, uncomplicated 1 Osteoporosis 2 Antimicrobial prophylaxis in surgery and other 1 Sof tissue injuries (e.g., strains, sprains, tendinitis, procedures bursitis, acute low back pain) 2 Antimicrobial stewardship 2 Rheumatoid arthritis 2 Bacterial resistance 3 Familial Mediterranean fever and other hereditary 2 Bloodstream and catheter infections autoinfammatory diseases 2 Bone and joint infections (e.g., osteomyelitis, prosthetic 3 Mixed connective tissue disease joint infections) 3 Myopathies (e.g., dermatomyositis, polymyositis) 2 Central nervous system (CNS) infections (e.g., 3 Reiter syndrome meningitis, encephalitis, brain abscess) 3 Rhabdomyolysis 2 Fungal infections, invasive (e.g., histoplasmosis, 3 Sjögren syndrome coccidioidomycosis, cryptococcosis, blastomycosis, 3 Spondyloarthritides (e.g., ankylosing spondylitis) hematogenous candidiasis, aspergillosis) 3 Systemic sclerosis 2 Gastrointestinal infections (e.g., infectious diarrhea, enterotoxigenic poisonings) 3 Vasculitides (e.g., polymyalgia rheumatica, temporal arteritis, granulomatosis with polyangiitis [Wegener 2 Health care–acquired infections: preventive measures granulomatosis]) 2 Hepatitis, viral Neurologic Disorders 2 Human immunodefciency virus (HIV) infection 1 Headache (e.g., tension-type, migraine, cluster) 2 Infections in immunocompromised patients (e.g., febrile 1 Pain, neuropathic (e.g., diabetic, postherpetic) neutropenia, opportunistic infections in AIDS) 1 Pain, nociceptive (acute and chronic) 2 Infective endocarditis 2 Epilepsy 2 Intra-abdominal infections (e.g., peritonitis, abscess) 2 Fibromyalgia 2 Microbiologic testing (including rapid diagnostic tests) 2 Multiple sclerosis 2 Parasitic diseases (e.g., protozoans [giardiasis, amebiasis, malaria, trypanosomiasis], helminths [nematodes, 2 Neurocognitive disorders (e.g., Alzheimer disease, schistosomiasis, trematodes, trichinellosis, cestodes], vascular and frontotemporal dementia) ectoparasites [head and body lice, scabies]) 2 Parkinson disease 2 Prostatitis 2 Sleep-wake disorders (e.g., narcolepsy, restless legs 2 Sepsis and septic shock syndrome, circadian
Load more

Recommended publications
  • Pharmacotherapy-Enhancing Drugs
    EDITORIAL NOTE Pharmacotherapy-Enhancing drugs Robin Karli* Karli R. Pharmacotherapy-Enhanced drugs. Clin Pharmacol Toxicol Res. 2021;4(2):1. DESCRIPTION Pharmacotherapy is related to several diseases and disorders. The medication varies from one disease or disorder to the other. Pharmacotherapy is provided to diseases and disorders related to Cardiovascular, respiratory, n the treatment of addiction, medications are wanted to reduce the gastrointestinal, renal, neurological, psychiatric, endocrinologic, gynecologic I intensity of withdrawal symptoms, reduce alcohol and other drug craving and obstetric, urological, immunologic, rheumatologic, ophthalmic, and reduce the likelihood of use or relapse for specific drugs by blocking dermatologic, hematologic, infectious diseases, oncologic and nutritional their effect. The primary goal of medication-assisted treatment is for the disorders. patient to achieve fully-sustained remission. SELECTION OF AN ANTIDEPRESSANT MEDICATION Pharmacotherapy is therapy using pharmaceutical drugs, as distinguished from therapy using surgery (surgical therapy), radiation (radiation therapy), movement (physical therapy), or other modes. Among The overall effectiveness of antidepressant medications is usually equivalent between and within classes of medicines. However, there are distinct physicians, sometimes the term medical therapy refers specifically to differences in individual patient response to and side effects caused by the pharmacotherapy as against surgical or other therapy; as an example, in classes of medicines and individual agents. The genetic differences within the oncology, medical oncology is thus distinguished from surgical oncology. metabolism of certain medications including antidepressants are often Pharmacists are experts in pharmacotherapy and are liable for ensuring determined by cytochrome P450 genetic testing. This testing may identify the safe, appropriate, and economical use of pharmaceutical drugs.
    [Show full text]
  • 16. Questions and Answers
    16. Questions and Answers 1. Which of the following is not associated with esophageal webs? A. Plummer-Vinson syndrome B. Epidermolysis bullosa C. Lupus D. Psoriasis E. Stevens-Johnson syndrome 2. An 11 year old boy complains that occasionally a bite of hotdog “gives mild pressing pain in his chest” and that “it takes a while before he can take another bite.” If it happens again, he discards the hotdog but sometimes he can finish it. The most helpful diagnostic information would come from A. Family history of Schatzki rings B. Eosinophil counts C. UGI D. Time-phased MRI E. Technetium 99 salivagram 3. 12 year old boy previously healthy with one-month history of difficulty swallowing both solid and liquids. He sometimes complains food is getting stuck in his retrosternal area after swallowing. His weight decreased approximately 5% from last year. He denies vomiting, choking, gagging, drooling, pain during swallowing or retrosternal pain. His physical examination is normal. What would be the appropriate next investigation to perform in this patient? A. Upper Endoscopy B. Upper GI contrast study C. Esophageal manometry D. Modified Barium Swallow (MBS) E. Direct laryngoscopy 4. A 12 year old male presents to the ER after a recent episode of emesis. The parents are concerned because undigested food 3 days old was in his vomit. He admits to a sensation of food and liquids “sticking” in his chest for the past 4 months, as he points to the upper middle chest. Parents relate a 10 lb (4.5 Kg) weight loss over the past 3 months.
    [Show full text]
  • Current Practices of Obesity Pharmacotherapy, Bariatric Surgery Referral and Coding for Counselling by Healthcare Professionals Christine Petrin, Scott Kahan, M
    Obesity Science & Practice doi: 10.1002/osp4.53 ORIGINAL ARTICLE Current practices of obesity pharmacotherapy, bariatric surgery referral and coding for counselling by healthcare professionals Christine Petrin, Scott Kahan, M. Turner, C. Gallagher and W. H. Dietz George Washington University, Summary Washington, DC, USA Introduction Received 21 April 2016; revised 7 June 2016; accepted 9 June 2016 Rates of obesity pharmacotherapy use, bariatric surgery and intensive behavioural counselling have been extremely low. Address for correspondence: C Petrin, Objectives George Washington University, 950 New Hampshire Ave NW Suite 300, Washington, DC 20037, USA. E-mail: cepetrin@gwmail. The primary objective of this study was to survey healthcare provider beliefs, practice gwu.edu and knowledge regarding obesity management. Methods Primary care physicians (PCPs), OB-GYN physicians and nurse practitioners (NPs) responded to a web-based survey related to drug therapy practice, bariatric surgery referral and reimbursement coding practice. Results Rates of reported use of obesity pharmacotherapy appear to be increasing among PCPs, which is likely related to the approval of four new obesity pharmacotherapy agents since 2012. Rates of pharmacotherapy use among OB-GYNs and NPs appear much lower. Similarly, few PCPs are averse to recommending bariatric surgery, but aversion among OB-GYNs and NPs is significantly higher. Conclusion Together, these observations suggest that OB-GYN and NP populations are important targets for education about obesity management. Very few PCPs, OB-GYNs or NPs use behavioural counselling coding for obesity. Better understanding of why this benefit is not being fully used could inform outreach to improve counselling rates. Keywords: Bariatric surgery referral, CPT coding, obesity counselling, obesity pharmacotherapy.
    [Show full text]
  • Pharmacotherapy Program Description 2020-2021
    PGY 1 & PGY 2 Pharmacotherapy Residency AMARILLO PROGRAM SUMMARY 2020-2021 !1 of 8! PGY 1 & PGY 2 PHARMACOTHERAPY - AMARILLO PURPOSE PGY1 Program PGY1 pharmacy residency programs build on Doctor of Pharmacy (Pharm.D.) education and outcomes to contribute to the development of clinical pharmacists responsible for medication-related care of patients with a wide range of conditions, eligible for board certification, and eligible for postgraduate year two (PGY2) pharmacy residency training. PGY2 Program PGY2 pharmacy residency programs build on Doctor of Pharmacy (Pharm.D.) education and PGY1 pharmacy residency programs to contribute to the development of clinical pharmacists in specialized areas of practice. PGY2 residencies provide residents with opportunities to function independently as practitioners by conceptualizing and integrating accumulated experience and knowledge and incorporating both into the provision of patient care or other advanced practice settings. Residents who successfully complete an accredited PGY2 pharmacy residency are prepared for advanced patient care, academic, or other specialized positions, along with board certification, if available. INTRODUCTION The PGY1/PGY2 Pharmacotherapy Residency is designed to produce a specialized practitioner with an advanced degree of proficiency and expertise in working with interdisciplinary teams to deliver comprehensive patient care to diverse populations from ambulatory care to critically ill, pediatric to geriatric ages, and presenting with varied and complex health problems.
    [Show full text]
  • ASHP Statement on Pharmaceutical Care
    Medication Therapy and Patient Care: Organization and Delivery of Services–Statements 331 ASHP Statement on Pharmaceutical Care The purpose of this statement is to assist pharmacists in under- Care. Central to the concept of care is caring, a personal standing pharmaceutical care. Such understanding must pre- concern for the well-being of another person. Overall cede efforts to implement pharmaceutical care, which ASHP patient care consists of integrated domains of care including believes merit the highest priority in all practice settings. (among others) medical care, nursing care, and pharmaceu- Possibly the earliest published use of the term pharma- tical care. Health professionals in each of these disciplines ceutical care was by Brodie in the context of thoughts about possess unique expertise and must cooperate in the patient’s drug use control and medication-related services.1,2 It is a overall care. At times, they share in the execution of the various term that has been widely used and a concept about which types of care (including pharmaceutical care). To pharma- much has been written and discussed in the pharmacy pro- ceutical care, however, the pharmacist contributes unique fession, especially since the publication of a paper by Hepler knowledge and skills to ensure optimal outcomes from the and Strand in 1990.3–5 ASHP has formally endorsed the con- use of medications. cept.6 With varying terminology and nuances, the concept At the heart of any type of patient care, there exists a has also been acknowledged by other national pharmacy or- one-to-one relationship between a caregiver and a patient.
    [Show full text]
  • Candida Ball in the Esophagus
    Case Report Adv Res Gastroentero Hepatol Volume 6 Issue 1 - June 2017 DOI: 10.19080/ARGH.2017.06.555677 Copyright © All rights are reserved by Mohammad Al-Shoha Case Report: Candida Ball in the Esophagus Mohammad Al-Shoha MD1*, Nayana George MD1 and Benjamin Tharian MD1,2 1Department of Internal Medicine, University of Arkansas for Medical Sciences, USA 2Department of Medicine, Division of Gastroenterology and Hepatology, USA Submission: February 10, 2017; Published: June 16, 2017 *Corresponding author: Mohammad Al-Shoha, Department of Internal Medicine, University of Arkansas for Medical Sciences, Internal Medicine, 4301 W. Markham Street, Slo t#634, Little Rock, AR 72205, USA, Tel: , Email: [email protected] Abstract Candida albicans is the most common well known cause of infectious esophagitis. Although most patients with Candida esophagitis are immunocompromised, about 25% have scleroderma, achalasia, or other causes of esophageal dysmotility that would allow the fungi to overgrow but it has been reported in the literature that it can manifest as an esophageal mass. We are reporting a case of recurrent esophageal candidiasis manifestingand colonize on the the esophagus, Esophagogastroduodenoscopy with subsequent esophagitis (EGD) as [1,2]. an obstructing Esophageal mass. candidiasis usually manifests as white mucosal plaque-like lesions Case report showed normal complete blood count, acute renal injury with A 70-year old African American male patient who presented creatinine 11.5mg/dL, sodium 127, potassium 3.9, normal with complaints of gradually worsening dysphagia for both TSH and negative HIV testing. Repeat EGD revealed a mass at solids and liquids with an EGD revealing a nearly obstructing 25cm from incisors (image A,B) with a biopsy revealing active mass in the esophagus 25cm from incisors occupying 75-99% of esophagitis with intraepithelial fungi consistent with Candida the circumference of the esophagus with the inability to traverse with no dysplasia and malignancy.
    [Show full text]
  • Pharmacy Services in Telepharmacy: How’S It Working, Where It’S Working, and What’S Required to Practice in This New Setting
    Advances in Pharmacy: Journal of Student Solutions to Pharmacy Challenges Volume 1 | Issue 1 Article 5 2017 Pharmacy Services in Telepharmacy: how’s it working, where it’s working, and what’s required to practice in this new setting. Aimee Skrei University of Minnesota - Twin Cities, [email protected] Michelle M. Rundquist [email protected] Follow this and additional works at: http://pubs.lib.umn.edu/advances Recommended Citation Skrei, Aimee and Rundquist, Michelle M. (2017) "Pharmacy Services in Telepharmacy: how’s it working, where it’s working, and what’s required to practice in this new setting.," Advances in Pharmacy: Journal of Student Solutions to Pharmacy Challenges: Vol. 1 : Iss. 1 , Article 5. Available at: http://pubs.lib.umn.edu/advances/vol1/iss1/5 This work is licensed under a Creative Commons Attribution-Noncommercial 4.0 License Advances in Pharmacy: Journal of Student Solutions to Pharmacy Challenges is published by the University of Minnesota Libraries Publishing. Pharmacy Services in Telepharmacy: how is it working, where is it working, and what is required to practice in this new setting Michelle Rundquist1 and Aimee Skrei1 1University of Minnesota College of Pharmacy, Minneapolis, MN, USA June 2017 Abstract Telepharmacy is a rapidly growing area of communication within pharmaceutical care delivery, es- pecially in rural areas. The purpose of this literature review was to determine where telepharmacy is currently being practiced within community and ambulatory pharmacy settings and the effectiveness of it. Additionally, state rules and regulations for the upper Midwest region were compared and con- trasted to analyze how specific states are addressing the use of telepharmacy practice within the specified settings.
    [Show full text]
  • Treatment of Gastric Candidiasis in Patients with Gastric Ulcer Disease: Are Antifungal Agents Necessary?
    Gut and Liver, Vol. 3, No. 1, March 2009, pp. 31-34 original article Treatment of Gastric Candidiasis in Patients with Gastric Ulcer Disease: Are Antifungal Agents Necessary? Min Kyu Jung, Seong Woo Jeon, Chang Min Cho, Won Young Tak, Young Oh Kweon, Sung Kook Kim, and Yong Hwan Choi Department of Internal Medicine, Kyungpook National University Hospital, Daegu, Korea Background/Aims: The inadequacy of information on ing; antimycotic therapy was advocated in such cases. By the treatment of gastric candidiasis with antifungal contrast, Minoli et al.3 and Gotlieb-Jensen et al.4 consid- agents promoted us to evaluate patients with fungal ered it an epiphenomenon without any significance. infections who had gastric ulcers and assess the However, because the issue remains unresolved we retro- need for proton-pump inhibitors or antifungal agents. spectively reviewed fungal infections in patients with gas- Methods: Sixteen patients were included in the study. tric ulcers to determine the need for proton pump in- The criterion for the diagnosis of candidiasis was find- hibitor and/or antifungal agents. ing yeast and hyphae in the tissue or an ulcer on histological sections of biopsy samples. Surface fungi were not considered infections. Results: In all cases MATERIALS AND METHODS with benign ulcers, follow-up endoscopy performed 6 weeks after proton-pump-inhibitor treatment revealed We reviewed the pathology specimens and medical re- that the ulcer had improved without antifungal medi- cords of patients with gastroduodenal ulcers diagnosed by cation. However, in patients with malignant ulcers, upper gastrointestinal endoscopy at Kyungpook National surgical resection was necessary for a definitive cure.
    [Show full text]
  • Pharmacotherapy for Adults with Alcohol Use Disorder in Outpatient
    Pharmacotherapy for Adults With Alcohol Use KEYDisorder ISSUE in Outpatient Settings Medications can be effective in treating alcohol use disorder Summary of Evidence From the Systematic Review (AUD) when used in combination with psychosocial interventions. üüAcamprosate and oral naltrexone improve alcohol consumption Evidence from epidemiological studies suggests that improving outcomes for patients with AUD. Head-to-head trials have not alcohol consumption outcomes (such as reduction in return to consistently established the superiority of one medication over drinking or in percentage of drinking days) would likely result in another. (See Table 1.) improved health outcomes. However, medications are underutilized üüEvidence related to injectable naltrexone is currently limited. in treating AUD, thus providing opportunities for expanding treatment optimization. This is a summary of a systematic review üüEvidence from randomized controlled trials does not support evaluating the efficacy, comparative effectiveness, and adverse the efficacy of disulfiram. effects of medications in adults with AUD. The systematic »üDisulfiram may be recommended to individuals who have review included 167 articles published from January 1, 1970, a goal of abstinence but for whom acamprosate and oral to October 11, 2013. The full report, listing all studies, is available naltrexone are not suitable or to individuals who prefer at www.effectivehealthcare.ahrq.gov/alcohol-disorder. disulfiram and understand its risks.4 BACKGROUND üüMost studies evaluated medications
    [Show full text]
  • Pharmacotherapy Content Outline
    BOARD OF PHARMACY SPECIALTIES PHARMACOTHERAPY SPECIALIST CERTIFICATION CONTENT OUTLINE/CLASSIFICATION SYSTEM FINALIZED SEPTEMBER 2015/FOR USE ON FALL 2016 EXAMINATION AND FORWARD UNDERSTANDING THE CONTENT OUTLINE/CLASSIFICATION SYSTEM The following domains, tasks, and knowledge statements were identified by the BPS Specialty Council on Pharmacotherapy and validated through a role delineation study, most recently updated in 2015. The proportion of examination items allotted to each domain was determined through analysis and discussion of the results of the role delineation study by the Specialty Council. Each of the major areas/domains of Pharmacotherapy practice noted below will be tested. Questions will not be grouped by domain. Items testing each domain are distributed throughout the total examination. Please note that this examination will SAMPLE a candidate’s knowledge rather than trying to test all of his/her knowledge. Questions in Domain 1 that deal with age-specific problems are reflected across all organ systems and patient-care problems. There is a mixture of chronic and acute care pharmacotherapy problems, with several questions that are not specific to a patient acuity level. Here is a brief primer to understand the structure of the content outline/classification system. Domains: A domain is a major responsibility or duty. You can think of a domain as a major heading in an outline format. You will see the domains displayed as black bars on the outline. Three domains are included in the content outline and are noted below. 1. Patient-Specific Pharmacotherapy (55 percent of examination) 2. Drug Information and Evidence-Based Medicine (25 percent of examination) 3.
    [Show full text]
  • The Impact of a Pharmacotherapy Consultation on the Cost and Outcome of Medical Therapy
    The Impact of a Pharmacotherapy Consultation on the Cost and Outcome of Medical Therapy John Jameson, PharmD; Glenn VanNoord, MD; and Karen Vanderwoud, PharmD fy Rapids and Grand Rapids, Michigan Uckground- One important task for physicians is to op­ ter the consultation, the number of drugs, the number timize their patients’ medication regimen. Involvement o f doses, and the 6-month drug costs all decreased in of clinical pharmacists who have specific training in drug the consult group and increased in the control group; regimen design has been associated with improved pa­ the net difference was 1.1 drugs (P = .0 0 4 ), 2.15 doses tient outcomes for specific medical conditions, eg, hyper­ per day (P = .0 0 7 ), $586 per year (P = .008). The side ef­ tension and anticoagulation. This prospective, randomized fects score improved by 1.8 points more in the consult trial investigated whether a single consultation by a clinical group compared with the control group (P=NS). Simi­ pharmacist with high-risk patients and their primary physi­ larly, the prescribing convenience score in the consult cians would result in improved prescribing outcomes. group improved by 1.4 points more than that o f the control group (P=NS). Methods. Patients at risk for medication-related prob­ lems were identified and randomized to receive a phar­ Conclusions. This study demonstrates several important macotherapy consultation (consult group) or usual benefits o f integration o f a clinical pharmacist into a pri­ medical care (control group). Outcomes, including the mary care setting, including improvement in cost and number o f drugs, number o f doses per day, cost of simplification of the medication regimen with no reduc­ medications, and patient reports of adverse effects, were tion in quality o f care.
    [Show full text]
  • Affordable, Quality, Long-Term Care and Pharmacotherapy of Chronic Diseases: a Framework for Low and Middle Income Countries
    ATMCC in LMIC Affordable, quality, long-term care and pharmacotherapy of chronic diseases: a framework for low and middle income countries Report Commissioned by The Alliance for Health Policy and System Research, World Health Organization, Geneva Submission 31 August 2011 Contributing authors: Veronika J. Wirtz, Warren A. Kaplan, Yared Santa-Ana Téllez, Ruy Lopez Ridaura 1 ATMCC in LMIC Executive summary Background: Even though global efforts to improve access to healthcare, particularly pharmacotherapy have focused mainly on HIV, tuberculosis and malaria, in many Low and Middle Income Countries (LMIC) chronic diseases are already the most prevalent causes of morbidity and mortality. Health systems in many LMIC are not designed to provide long-term care for chronic diseases as, among other things, they lack a comprehensive approach to provide accessible, affordable long-term pharmacotherapy as part of a care package. Objectives: To propose a framework of accessible and affordable pharmacotherapy for chronic diseases that may be applied in resource poor settings. Design: Systematic literature review of the following databases: PubMed, EMBASE, ISI Web of Science and the International Network for Rational Use of Drugs (INRUD). Review of descriptive and interventional studies on accessibility, affordability of pharmacotherapy for diabetes, asthma and depression and publications proposing chronic care management models with particular focus on LMIC. Results: 1. The barriers to access to pharmacotherapy and related routine care for diabetes, asthma and depression in LMIC are similar to those for acute diseases: affordability of medicines, accessibility in the public and private sector, scarcity of diagnostic and monitoring equipment, lack of trained human resources to provide treatment, paucity of patient and community empowerment strategies among others.
    [Show full text]